Business
Endonovo Therapeutics Announces International Expansion with Distribution Agreement for SofPulse® in Taiwan, Republic of China
Endonovo Therapeutics Announces International Expansion with Distribution Agreement for SofPulse® in Taiwan, Republic of China.
About this update from Endonovo Therapeutics, Inc.
[{"type":"text","content":"\n Los Angeles, CA, June 01, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) (\"Endonovo\" or the \"Company\") today announced the signing of a Sales and Strategic Partnership Agreement with Evermed Medical Enterprise Ltd., a leading medical device distributor in Taiwan, ROC (Republic of China) to distribute SofPulse®. Alan Collier, Chief Executive Officer of Endonovo, commented, “In line with our strategy to expand the SofPulse® global footprint in our postoperative distribution model, we are pleased to announce our agreement with Evermed Medical Enterprise Ltd., a leading medical device distributor in Taiwan. Evermed has an established sales and distribution network throughout Taiwan specific to the operative and postoperative surgical market. Endonovo's international expansion of SofPulse® devices into that market is a perfect fit allowing us to establish a solid distribution presence in Taiwan and future expansion into other International markets.” Evermed’s Chief Executive Officer, Mr. George Wang, commented, “We are excited to partner with Endonovo Therapeutics to introduce SoftPulse®, a proven drug-free, postoperative pain and edema reduction device, to the Taiwan Surgical market. Our company has been searching for new innovative, easy-to-use, non-invasive solution for the reduction of pain and edema to introduce and distribute in Taiwan. We feel the SofPulse® device with its proven results in successfully reducing pain and edema in surgical operations is the best product to offer our Taiwanese distribution network.” Mr. Wang continues, “Evermed has experience in successful submittals and approvals for the TFDA Quality System Documentation (QSD) system and obtaining Product Permit License for the Taiwanese Medical device market. We feel our organization, upon obtaining TFDA approvals, will be able to effectively establish and expand distribution throughout the Taiwan surgical markets. Our sales and distribution offices and teams are strategically located in Taipei, Taichung, Kaohsiung/Tainan which allows us to effectively service Taiwan's 23-million person population, hospitals and medical centers. We look forward to having a long-term partnership with Endonovo as we establish and expand the postoperative surgical market with the SofPulse®...